Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333374 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL28763194 | 0.79 | MEN1 (0.42) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL7572487 | 0.79 | SLC6A2 (0.46) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL25112007 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL11852260 | 0.77 | GAA (0.47) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL28241893 | 0.76 | ALDH1A1 (0.39) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL534412 | 0.74 | SLC6A2 (0.50) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL21255141 | 0.73 | SLC6A2 (0.41) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL14060360 | 0.73 | ALDH1A1 (0.46) | SLC6A2SLC6A4ALDH1A1MEN1USP2 | |
| SCHEMBL11729757 | 0.72 | SLC6A2 (0.46) | SLC6A2SLC6A4ALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405454-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017125932-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-07-27 | — | — | WO | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311808-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358161-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002055501-A2 | N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMGEN INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | SLC6A2 89/4885SLC6A4 224/4885ALDH1A1 389/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SLC6A2 584/4885SLC6A4 672/4885ALDH1A1 178/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | SLC6A2 563/4885SLC6A4 811/4885ALDH1A1 261/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SLC6A2 646/4885SLC6A4 936/4885ALDH1A1 327/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SLC6A2 584/4885SLC6A4 672/4885ALDH1A1 178/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | SLC6A2 50/4885SLC6A4 165/4885ALDH1A1 192/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | SLC6A2 2537/4885SLC6A4 2804/4885ALDH1A1 540/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SLC6A2 584/4885SLC6A4 672/4885ALDH1A1 178/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | SLC6A2 50/4885SLC6A4 165/4885ALDH1A1 192/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SLC6A2 646/4885SLC6A4 936/4885ALDH1A1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.